Carotid artery surgery improves ocular blood flow in OIS

Article

Cartotid artery surgery significantly improves ocular blood flow in patients with acute and chronic forms of ocular ishaemic syndrome (OIS), claims a study in Eye.

Carotid artery surgery significantly improves ocular blood flow in patients with acute and chronic forms of ocular ishaemic syndrome (OIS), claims a study in Eye.

Dr V. V. Neroev et al., The Helmholtz Moscow Research Institute of Eye Diseases, Moscow, Russia, conducted a study on 180 patients with OIS. Of the participants, 104 had acute forms of OIS and 76 had chronic OIS.

All patients were assessed preoperatively and six and twelve months postoperatively. The outcome measures included visual acuity, electrophysiological investigations (the threshold of electrical sensitivity (TES) and the level of liability of optic nerve (LON)) and blood flow in orbital vessels.

TES and LON improved postoperatively and visual acuity increased in patients with acute OIS. At six and twelve months postoperatively, the mean indices of blood-flow velocities in the ophthalmic artery, the central retinal artery and the posterior ciliary arteries increased.

The abstract can be found here.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.